Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
Quick Facts
Expected listing date: July 21, 2026
Exchange: NASDAQ
Proposed symbol: HLTH
Price range: 15 - 17
Status: Priced
Company Overview
Cue Health is a San Diego-based health technology and diagnostics company built around its Cue Integrated Care Platform. The system combines a reusable Cue Reader, single-use Cue Cartridges, a sample collection Cue Wand, cloud software, consumer and clinician apps, and integrations with EMR systems, pharmacies, clinician networks, and labs. Its first commercial product was the Cue COVID-19 Test Kit, authorized for point-of-care and at-home use, and by 2023 the company had expanded into at-home testing for sexual health, heart health, women’s health, metabolic health, wellness, and telehealth follow-up through Cue Care.
The company was founded in 2010 and is headquartered in San Diego, California. Its pitch is broader than a single test: Cue is trying to build a connected diagnostics platform that can move lab-quality testing outside traditional settings and into homes, clinics, and digital care workflows. That puts it in a competitive market that includes large diagnostics incumbents such as Abbott, Roche, Danaher/Cepheid, and QuidelOrtho, plus newer home-testing and digital-health players. The broader industry backdrop is consumerized healthcare, home testing, telehealth integration, and digital delivery of results, but the same market also carries FDA oversight, reimbursement pressure, and intense pricing competition.
Why They're Going Public
In the IPO prospectus, Cue said it intended to use net proceeds for general corporate purposes, including working capital and other business needs. The filing does not lay out a more detailed capital allocation plan in the summary language available here.
Going public also gives Cue a more visible currency for growth, partnerships, and scale-up as it tries to expand beyond COVID testing into a broader diagnostics platform. That matters because the company’s strategy depends on manufacturing capacity, regulatory clearances, and continued adoption of its connected-care model.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Cue’s financial profile was unusually strong in 2021. The company reported $618.1 million of revenue in 2021, up from $23.0 million in 2020, which works out to roughly 2,587% year-over-year growth. About $615.8 million of 2021 revenue came from product sales, showing how heavily the business was tied to test-kit demand.
Profitability also swung sharply positive. Cue reported net income of $86.4 million in 2021, compared with a $47.4 million net loss in 2020, and product gross margin improved to 55.1% from 2.9% a year earlier. The company ended 2021 with $409.9 million in cash and cash equivalents, giving it a meaningful balance-sheet cushion, though the durability of that earnings power depends on whether demand and product mix hold up after the pandemic surge.
Risk Factors
The biggest risk is concentration: Cue’s revenue base has been heavily dependent on a small number of customers. In the 2021 annual report, two customers represented 62% and 25% of total product revenue, and the IPO prospectus said a single non-government enterprise customer accounted for $28.9 million of revenue in the first half of 2021. That kind of concentration can make results lumpy and leaves the company exposed if one buyer pulls back.
Regulatory and demand risk are just as important. Cue’s business depends on maintaining existing FDA authorizations and obtaining new ones for future tests, while the company also faces competition, reimbursement pressure, and the need to scale manufacturing to meet demand and contractual obligations. The other issue is narrative risk: the IPO story was built around COVID testing and the broader adoption of the Cue platform, so shareholders should watch whether the company can prove that the platform works as a durable recurring business rather than a pandemic spike with a shorter shelf life.
Comparable Public Companies
The closest public comps are Abbott (ABT), Danaher (DHR), QuidelOrtho (QDEL), Exact Sciences (EXAS), and Guardant Health (GH). Abbott and Danaher are much larger, diversified diagnostics and medtech names, while QuidelOrtho is the more direct diagnostics peer. Exact Sciences and Guardant Health are useful for how the market prices diagnostics businesses with growth narratives but uneven profitability.
Against that group, Cue came public as a smaller, more concentrated, and more event-driven story. Its 2021 revenue base was huge relative to its earlier history, but that revenue was tied to COVID testing and a narrow customer set, which makes it less comparable to diversified incumbents and more exposed to normalization risk.
The sector backdrop has been mixed. Over the last 6 to 12 months, Abbott and Danaher have generally been mixed to modestly positive, QuidelOrtho has been weak and under pressure, and Exact Sciences and Guardant Health have been mixed to weak. Diagnostics names are typically valued on P/S or EV/Sales when profitability is volatile, and this group has not been trading like a uniformly hot sector.
Verdict
Cue Health priced its IPO at $16.00 per share, right in the middle of the $15 to $17 range, and the deal raised $200.0 million gross on 12.5 million base shares. That tells you the market was willing to fund the story, but not at a stretched price, which fits a company with real revenue and profitability but a business mix still tied to pandemic-era demand and a concentrated customer base.
The setup favors a watchful read rather than a simple momentum trade. The IPO window for healthcare was still open, but more selective than the 2020 to early-2021 peak, and Cue’s narrative was compelling because it combined connected diagnostics, at-home testing, and telehealth integration. What makes it noteworthy right now is that it was one of the clearer attempts to turn a COVID beneficiary into a broader diagnostics platform; shareholders should watch whether that transition can sustain growth after the initial testing surge fades.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
